The emergence of SARS-CoV-2 variants poses a risk for vaccine effectiveness and long-term immunity, and it is therefore crucial to develop and determine the effectiveness of vaccines to elicit broader cell mediated immune responses which likely fights better against currently circulating and new viral variants. Most commercial COVID-19 vaccines primarily target the S protein except a couple of traditional inactivated virus vaccines. This evidence concerns the gene PROS1 and COVID-19.